Business development

Glenmark is a USD 1.5 bn global pharmaceutical organisation with over 14,000 employees in 50 countries, deriving more than 70% of our revenues from international markets. Our 14 manufacturing facilities across four countries, manufacture 300+ molecules and 20+ dosage forms, and support our commercial presence across 80 countries. Glenmark has a significant presence in the branded generics markets across emerging economies including India. The Generics business of Glenmark services the requirements of the US and Western European markets. Glenmark’s API business sells its products in over 80 countries, including the US, various countries in the European Union, South America and India.

Key highlights:

  • Among the Top 80* Pharma & Biotech companies of the world
  • 5th fastest growing company (among Top 20 companies), in India (MAT March 2019)
  • 2nd in Dermatology, 4th in Respiratory, 6th in Cardiac segmentsin India^
  • 3 prescriptions/ second filled by Glenmark products in the US
  • One of the leading companies in the generic Dermatology segment in the US
  • 11th in the Dermatology market in Russia^

Partnership is an integral part of our business strategy and we are keen to collaborate with partners who support us in our mission of enriching lives of patients by offering them high-quality and affordable medication.


We are currently interested in in-licensing products that strengthen our presence globally and complement our existing product portfolio in the following therapies:

  • Dermatology
  • Respiratory
  • Oncology
  • Cardiovascular
  • Diabetes


We aim to explore new markets and expand our reach by collaborating. We look forward to partner with companies to introduce Glenmark products in countries like China, Korea, Australia, New Zealand, Turkey, Indonesia and Taiwan.

For queries, please email to

Note : *(SCRIP 100 Rankings published in the year 2019); ^ (IQVIA data)